115 results
Page 4 of 6
6-K
EX-99.1
bk54xc18k1c r247osn
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
8pccwgs7f jp7n3
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.2
b53pt busnej8
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.1
3kv x7ihllnyk6sa2d
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.1
ndcopjq ly
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
424B5
i2ub6
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
6sz1 vymyvi8mn
14 Aug 20
Current report (foreign)
4:24pm
6-K
EX-99.3
ai6e7 ok1bqsyllv
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.2
lv24hmz9
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
7kyw1e1ucoll7r
7 Jul 20
Current report (foreign)
3:39pm
6-K
EX-99.1
obmgn t4spo3c3v4
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
8w5g4w3eb4tds7cc
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.1
u3s0kba vf
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.3
397 mcrn0it
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.2
7r3sv3j642t wjwxdqb
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
5r708
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm
6-K
3opmo dg9w6hps
15 Jan 20
Current report (foreign)
8:35pm
6-K
EX-99.1
64g9a
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am